Clinical Trials Browser

Phase 3 × Metastatic Hormone Sensitive Prostate Cancer × enzalutamide × Clear all

NCT04076059 2026-02-06

China ARCHES

Phase 3 Active not recruiting

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT02677896 2025-10-24

ARCHES

Phase 3 Completed

1,150 enrolled 23 charts 1 FDA

Metastatic Hormone Sensitive Prostate Cancer